Eledon Pharmaceuticals Highlights Recent Business Milestones and Provides 2024 Outlook
Reported updated data from ongoing Phase 1b trial in kidney transplantation demonstrating tegoprubart treatment successfully prevented kidney transplant rejection and was generally safe and well-tolerated
Related news for (ELDN)
- Eledon Pharmaceuticals Reports Fourth Quarter and Full Year 2024 Operating and Financial Results
- Eledon Pharmaceuticals Announces Use of Tegoprubart as Key Component of Immunosuppression Regimen in its Second Transplant of a Genetically Modified Pig Kidney into a Human
- Eledon Pharmaceuticals Highlights Recent Business Milestones and Provides 2025 Outlook
- eledon pharmaceuticals announces pricing of $85 million underwritten offering of common stock and pre-funded warrants
- eledon pharmaceuticals announces positive initial data from subjects with type 1 diabetes treated with tegoprubart as part of an immunosuppression regimen following islet transplantation in investigator-initiated trial at uchicago medicine